10 XP 0   0   5  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

EGTX (Egetis) Stock Analysis
Buy, Hold or Sell?

Let's analyze Egetis together

I guess you are interested in Egetis Therapeutics AB (publ). Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • πŸ“Š Fundamental Analysis (FA) – Egetis’s Financial Insights
  • πŸ“ˆ Technical Analysis (TA) – Egetis’s Price Targets

I'm going to help you getting a better view of Egetis Therapeutics AB (publ). At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Egetis Therapeutics AB (publ)

I send you an email if I find something interesting about Egetis Therapeutics AB (publ).

1. Quick Overview

1.1. Quick analysis of Egetis (30 sec.)










1.2. What can you expect buying and holding a share of Egetis? (30 sec.)

How much money do you get?

How much money do you get?
kr0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
kr1.20
Expected worth in 1 year
kr1.08
How sure are you?
20.0%

+ What do you gain per year?

Total Gains per Share
kr-0.12
Return On Investment
-2.5%

For what price can you sell your share?

Current Price per Share
kr4.71
Expected price per share
kr3.025 - kr5.17
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Egetis (5 min.)




Live pricePrice per Share (EOD)
kr4.71
Intrinsic Value Per Share
kr-9.23 - kr-5.59
Total Value Per Share
kr-8.04 - kr-4.39

2.2. Growth of Egetis (5 min.)




Is Egetis growing?

Current yearPrevious yearGrowGrow %
How rich?$45.3m$53.2m-$10.2m-23.7%

How much money is Egetis making?

Current yearPrevious yearGrowGrow %
Making money-$8.6m-$8.5m-$117.7k-1.4%
Net Profit Margin-738.2%-734.6%--

How much money comes from the company's main activities?

2.3. Financial Health of Egetis (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#426 / 872

Most Revenue
#442 / 872

Most Profit
#510 / 872

Most Efficient
#677 / 872
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Egetis?

Welcome investor! Egetis's management wants to use your money to grow the business. In return you get a share of Egetis.

First you should know what it really means to hold a share of Egetis. And how you can make/lose money.

Speculation

The Price per Share of Egetis is kr4.705. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Egetis.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Egetis, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is kr1.20. Based on the TTM, the Book Value Change Per Share is kr-0.03 per quarter. Based on the YOY, the Book Value Change Per Share is kr-0.11 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is kr0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Egetis.

How much money are you going to get?

 MRQTTMYOY3Y5Y10Y
 kr% of Price per Sharekr% of Price per Sharekr% of Price per Sharekr% of Price per Sharekr% of Price per Sharekr% of Price per Share
Usd Eps-0.02-0.4%-0.02-0.5%-0.02-0.5%-0.02-0.5%-0.02-0.4%-0.01-0.2%
Usd Book Value Change Per Share-0.02-0.4%0.00-0.1%-0.01-0.2%0.000.0%0.000.1%0.000.1%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.02-0.4%0.00-0.1%-0.01-0.2%0.000.0%0.000.1%0.000.1%
Usd Price Per Share0.42-0.55-0.55-0.55-0.56-1.39-
Price to Earnings Ratio-5.73--5.66--5.84--6.47--10.47--78.64-
Price-to-Total Gains Ratio-22.81--13.61--11.61--10.42--31.17--292.54-
Price to Book Ratio3.33-4.61-3.75-3.91-4.52-64.65-
Price-to-Total Gains Ratio-22.81--13.61--11.61--10.42--31.17--292.54-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.4926135
Number of shares2029
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.000.00
Usd Total Gains Per Share0.000.00
Gains per Quarter (2029 shares)-6.266.74
Gains per Year (2029 shares)-25.0526.97
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-25-3502717
20-50-6005444
30-75-8508171
40-100-110010898
50-125-1350135125
60-150-1600162152
70-175-1850189179
80-200-2100216206
90-225-2350243233
100-251-2600270260

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.020.00.00.0%1.039.00.02.5%1.058.00.01.7%
Book Value Change Per Share1.03.00.025.0%4.08.00.033.3%5.015.00.025.0%8.032.00.020.0%14.044.01.023.7%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.040.00.0%0.00.059.00.0%
Total Gains per Share1.03.00.025.0%4.08.00.033.3%5.015.00.025.0%8.032.00.020.0%14.044.01.023.7%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Egetis Therapeutics AB (publ) compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-3Y+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.175-0.029-83%-0.109-38%-0.016-91%0.032-650%0.024-814%
Book Value Per Share--1.1971.143+5%1.417-15%1.399-14%1.355-12%0.977+23%
Current Ratio--1.5331.484+3%2.875-47%3.657-58%4.205-64%11.848-87%
Debt To Asset Ratio--0.4020.4020%0.207+94%0.225+79%0.215+87%0.150+168%
Debt To Equity Ratio--0.6710.676-1%0.281+139%0.343+96%0.312+115%0.205+227%
Dividend Per Share----0%-0%-0%-0%-0%
Enterprise Value--1424101120.9151836815422.629-22%1954388154.240-27%1964748311.170-28%1974041321.932-28%4888372215.599-71%
Eps---0.174-0.230+33%-0.228+31%-0.209+20%-0.163-6%-0.106-39%
Ev To Ebitda Ratio---6.860-6.191-10%-6.297-8%-7.159+4%-11.382+66%-80.345+1071%
Ev To Sales Ratio--28.03340.681-31%42.555-34%58.581-52%74.907-63%396.670-93%
Free Cash Flow Per Share---0.184-0.166-10%-0.177-4%-0.165-10%-0.136-26%-0.091-50%
Free Cash Flow To Equity Per Share---0.2050.018-1263%0.006-3487%0.039-626%0.017-1289%0.018-1254%
Gross Profit Margin--1.3281.3280%1.133+17%1.173+13%1.104+20%1.052+26%
Intrinsic Value_10Y_max---5.590----------
Intrinsic Value_10Y_min---9.234----------
Intrinsic Value_1Y_max---0.394----------
Intrinsic Value_1Y_min---0.711----------
Intrinsic Value_3Y_max---1.311----------
Intrinsic Value_3Y_min---2.334----------
Intrinsic Value_5Y_max---2.380----------
Intrinsic Value_5Y_min---4.162----------
Market Cap1690214865.280+15%1442101120.9151873815422.629-23%1891388154.240-24%1903492477.836-24%1917167671.932-25%4755564415.599-70%
Net Profit Margin---4.953-7.382+49%-7.346+48%-8.397+70%-7.519+52%-7.773+57%
Operating Margin----5.7880%-7.2250%-7.8750%-7.1910%-7.7180%
Operating Ratio--6.0948.204-26%8.197-26%9.209-34%8.421-28%8.566-29%
Pb Ratio3.930+15%3.3284.613-28%3.755-11%3.913-15%4.520-26%64.650-95%
Pe Ratio-6.767-18%-5.732-5.663-1%-5.838+2%-6.469+13%-10.473+83%-78.635+1272%
Price Per Share4.705+15%3.9855.209-23%5.265-24%5.296-25%5.335-25%13.237-70%
Price To Free Cash Flow Ratio-6.401-18%-5.421-8.008+48%-8.301+53%-8.318+53%-11.057+104%-79.313+1363%
Price To Total Gains Ratio-26.929-18%-22.808-13.613-40%-11.614-49%-10.422-54%-31.171+37%-292.542+1183%
Quick Ratio--1.5291.426+7%2.810-46%3.547-57%4.100-63%11.617-87%
Return On Assets---0.087-0.122+40%-0.128+48%-0.115+32%-0.100+15%-0.106+22%
Return On Equity---0.145-0.205+41%-0.161+11%-0.156+8%-0.132-9%-0.130-10%
Total Gains Per Share---0.175-0.029-83%-0.109-38%-0.016-91%0.032-650%0.024-814%
Usd Book Value--45366510.00043089285.000+5%53289682.500-15%52651640.700-14%50983931.985-11%36743412.765+23%
Usd Book Value Change Per Share---0.018-0.003-83%-0.011-38%-0.002-91%0.003-650%0.003-814%
Usd Book Value Per Share--0.1250.120+5%0.148-15%0.146-14%0.142-12%0.102+23%
Usd Dividend Per Share----0%-0%-0%-0%-0%
Usd Enterprise Value--149103387.360192314574.749-22%204624439.749-27%205709148.179-28%206682126.406-28%511812570.973-71%
Usd Eps---0.018-0.024+33%-0.024+31%-0.022+20%-0.017-6%-0.011-39%
Usd Free Cash Flow---6962550.000-6255825.000-10%-6658920.000-4%-6223350.550-11%-5099167.455-27%-3436910.993-51%
Usd Free Cash Flow Per Share---0.019-0.017-10%-0.019-4%-0.017-10%-0.014-26%-0.010-50%
Usd Free Cash Flow To Equity Per Share---0.0210.002-1263%0.001-3487%0.004-626%0.002-1289%0.002-1254%
Usd Market Cap176965496.395+15%150987987.360196188474.749-23%198028339.749-24%199295662.429-24%200727455.251-25%497907594.313-70%
Usd Price Per Share0.493+15%0.4170.545-23%0.551-24%0.555-25%0.559-25%1.386-70%
Usd Profit---6585630.000-8677012.500+32%-8559225.000+30%-7804573.575+19%-6091226.130-8%-3954087.113-40%
Usd Revenue--1329690.0001224990.000+9%1643790.000-19%1149606.000+16%1078692.690+23%895889.108+48%
Usd Total Gains Per Share---0.018-0.003-83%-0.011-38%-0.002-91%0.003-650%0.003-814%
 EOD+5 -3MRQTTM+18 -19YOY+10 -273Y+12 -255Y+9 -2810Y+12 -25

3.3 Fundamental Score

Let's check the fundamental score of Egetis Therapeutics AB (publ) based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-6.767
Price to Book Ratio (EOD)Between0-13.930
Net Profit Margin (MRQ)Greater than0-4.953
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than11.529
Current Ratio (MRQ)Greater than11.533
Debt to Asset Ratio (MRQ)Less than10.402
Debt to Equity Ratio (MRQ)Less than10.671
Return on Equity (MRQ)Greater than0.15-0.145
Return on Assets (MRQ)Greater than0.05-0.087
Total4/10 (40.0%)

3.4 Technical Score

Let's check the technical score of Egetis Therapeutics AB (publ) based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5058.009
Ma 20Greater thanMa 504.526
Ma 50Greater thanMa 1004.007
Ma 100Greater thanMa 2004.081
OpenGreater thanClose4.550
Total2/5 (40.0%)

4. In-depth Analysis

4.1 About Egetis Therapeutics AB (publ)

Egetis Therapeutics AB (publ), a pharmaceutical company, focuses on projects in late-stage development for the treatment of serious diseases with unmet medical needs in the orphan drug segment. The company's products pipeline includes Aladote, a drug to reduce the risk of acute liver injury associated with acetaminophen/paracetamol overdose, which is in phase IIb/III clinical trial; and Emcitate, a drug for the treatment of monocarboxylate transporter 8 (MCT8) deficiency, a debilitating rare disease with no available treatment. The company was formerly known as PledPharma AB (publ) and changed its name to Egetis Therapeutics AB (publ) in December 2020. Egetis Therapeutics AB (publ) was incorporated in 2006 and is based in Stockholm, Sweden.

Fundamental data was last updated by Penke on 2025-06-29 03:51:05.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is just able to pay all its short-term debts.
The company is able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is fair priced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profitΒ Egetis earns for each kr1 of revenue.

  • Above 10% is considered healthy but always compareΒ Egetis to theΒ Biotechnology industry mean.
  • A Net Profit Margin of -495.3%Β means thatΒ kr-4.95 for each kr1Β in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Egetis Therapeutics AB (publ):

  • The MRQ is -495.3%. The company is making a huge loss. -2
  • The TTM is -738.2%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-495.3%TTM-738.2%+242.9%
TTM-738.2%YOY-734.6%-3.5%
TTM-738.2%5Y-751.9%+13.7%
5Y-751.9%10Y-777.3%+25.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-495.3%-91.7%-403.6%
TTM-738.2%-140.3%-597.9%
YOY-734.6%-196.4%-538.2%
3Y-839.7%-247.9%-591.8%
5Y-751.9%-343.3%-408.6%
10Y-777.3%-488.1%-289.2%
4.3.1.2. Return on Assets

Shows howΒ efficientΒ Egetis is using its assets to generate profit.

  • Above 5% is considered healthyΒ but always compareΒ Egetis to theΒ Biotechnology industry mean.
  • -8.7% Return on Assets means thatΒ Egetis generatedΒ kr-0.09 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Egetis Therapeutics AB (publ):

  • The MRQ is -8.7%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -12.2%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-8.7%TTM-12.2%+3.5%
TTM-12.2%YOY-12.8%+0.6%
TTM-12.2%5Y-10.0%-2.2%
5Y-10.0%10Y-10.6%+0.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-8.7%-11.5%+2.8%
TTM-12.2%-11.5%-0.7%
YOY-12.8%-11.4%-1.4%
3Y-11.5%-11.7%+0.2%
5Y-10.0%-11.9%+1.9%
10Y-10.6%-13.7%+3.1%
4.3.1.3. Return on Equity

Shows how efficient Egetis is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compareΒ Egetis to theΒ Biotechnology industry mean.
  • -14.5% Return on Equity means Egetis generated kr-0.15Β for eachΒ kr1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Egetis Therapeutics AB (publ):

  • The MRQ is -14.5%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -20.5%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-14.5%TTM-20.5%+6.0%
TTM-20.5%YOY-16.1%-4.3%
TTM-20.5%5Y-13.2%-7.3%
5Y-13.2%10Y-13.0%-0.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-14.5%-13.6%-0.9%
TTM-20.5%-14.8%-5.7%
YOY-16.1%-14.4%-1.7%
3Y-15.6%-16.8%+1.2%
5Y-13.2%-17.5%+4.3%
10Y-13.0%-19.5%+6.5%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Egetis Therapeutics AB (publ).

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

MeasuresΒ how efficient Egetis is operatingΒ .

  • Measures how much profit Egetis makes for each kr1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compareΒ Egetis to theΒ Biotechnology industry mean.
  • An Operating Margin of 0.0%Β means the company generated kr0.00 Β for each kr1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Egetis Therapeutics AB (publ):

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-578.8%+578.8%
TTM-578.8%YOY-722.5%+143.6%
TTM-578.8%5Y-719.1%+140.2%
5Y-719.1%10Y-771.8%+52.7%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--221.8%+221.8%
TTM-578.8%-250.7%-328.1%
YOY-722.5%-208.5%-514.0%
3Y-787.5%-220.2%-567.3%
5Y-719.1%-342.4%-376.7%
10Y-771.8%-462.5%-309.3%
4.3.2.2. Operating Ratio

Measures how efficient Egetis is keepingΒ operating costsΒ low.

  • Below 1 is considered healthy (always compare toΒ Biotechnology industry mean).
  • An Operation Ratio of 6.09 means that the operating costs are kr6.09 for each kr1 in net sales.

Let's take a look of the Operating Ratio trends of Egetis Therapeutics AB (publ):

  • The MRQ is 6.094. The company is inefficient in keeping operating costs low. -1
  • The TTM is 8.204. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ6.094TTM8.204-2.110
TTM8.204YOY8.197+0.007
TTM8.2045Y8.421-0.217
5Y8.42110Y8.566-0.145
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ6.0942.097+3.997
TTM8.2042.684+5.520
YOY8.1973.076+5.121
3Y9.2093.524+5.685
5Y8.4214.724+3.697
10Y8.5666.445+2.121
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Egetis Therapeutics AB (publ).

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Egetis is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare toΒ Biotechnology industry mean).
  • A Current Ratio of 1.53Β means the company has kr1.53 in assets for each kr1 in short-term debts.

Let's take a look of the Current Ratio trends of Egetis Therapeutics AB (publ):

  • The MRQ is 1.533. The company is able to pay all its short-term debts. +1
  • The TTM is 1.484. The company is just able to pay all its short-term debts.
Trends
Current periodCompared to+/- 
MRQ1.533TTM1.484+0.049
TTM1.484YOY2.875-1.391
TTM1.4845Y4.205-2.721
5Y4.20510Y11.848-7.643
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.5333.638-2.105
TTM1.4843.846-2.362
YOY2.8754.140-1.265
3Y3.6574.688-1.031
5Y4.2055.722-1.517
10Y11.8486.144+5.704
4.4.3.2. Quick Ratio

Measures if Egetis is able to pay off Short-term Debt but only usingΒ theΒ most liquid assets.

  • Above 1 is considered healthy butΒ always compareΒ Egetis to theΒ Biotechnology industry mean.
  • A Quick Ratio of 1.53Β means the company can pay off kr1.53 for each kr1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Egetis Therapeutics AB (publ):

  • The MRQ is 1.529. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 1.426. The company is able to pay all its short-term debts with the most liquid assets. +1
Trends
Current periodCompared to+/- 
MRQ1.529TTM1.426+0.103
TTM1.426YOY2.810-1.384
TTM1.4265Y4.100-2.674
5Y4.10010Y11.617-7.517
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.5292.826-1.297
TTM1.4263.116-1.690
YOY2.8103.786-0.976
3Y3.5474.311-0.764
5Y4.1005.702-1.602
10Y11.6176.335+5.282
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Egetis Therapeutics AB (publ).

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much %Β of EgetisΒ assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compareΒ Egetis to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.40Β means that Egetis assets areΒ financed with 40.2% credit (debt) and the remaining percentage (100% - 40.2%)Β is financed by its owners/shareholders.Β 

Let's take a look of the Debt to Asset Ratio trends of Egetis Therapeutics AB (publ):

  • The MRQ is 0.402. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.402. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.402TTM0.4020.000
TTM0.402YOY0.207+0.195
TTM0.4025Y0.215+0.187
5Y0.21510Y0.150+0.065
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.4020.327+0.075
TTM0.4020.349+0.053
YOY0.2070.332-0.125
3Y0.2250.340-0.115
5Y0.2150.346-0.131
10Y0.1500.378-0.228
4.5.4.2. Debt to Equity Ratio

Measures ifΒ Egetis is able toΒ pay off its debts by usingΒ shareholders equity.

  • Below 2 is considered healthy butΒ always compareΒ Egetis to theΒ Biotechnology industry mean.
  • A Debt to Equity ratio of 67.1% means that company has kr0.67 debt for each kr1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Egetis Therapeutics AB (publ):

  • The MRQ is 0.671. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.676. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.671TTM0.676-0.004
TTM0.676YOY0.281+0.395
TTM0.6765Y0.312+0.363
5Y0.31210Y0.205+0.107
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.6710.383+0.288
TTM0.6760.438+0.238
YOY0.2810.414-0.133
3Y0.3430.450-0.107
5Y0.3120.457-0.145
10Y0.2050.512-0.307
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

MeasuresΒ how much money you payΒ for each share forΒ every kr1 in earnings Egetis generates.

  • Above 15 is considered overpriced butΒ always compareΒ Egetis to theΒ Biotechnology industry mean.
  • A PE ratio of -5.73 means the investor is paying kr-5.73Β for every kr1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Egetis Therapeutics AB (publ):

  • The EOD is -6.767. Based on the earnings, the company is expensive. -2
  • The MRQ is -5.732. Based on the earnings, the company is expensive. -2
  • The TTM is -5.663. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-6.767MRQ-5.732-1.036
MRQ-5.732TTM-5.663-0.069
TTM-5.663YOY-5.838+0.175
TTM-5.6635Y-10.473+4.811
5Y-10.47310Y-78.635+68.162
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-6.767-2.399-4.368
MRQ-5.732-2.092-3.640
TTM-5.663-2.625-3.038
YOY-5.838-3.784-2.054
3Y-6.469-3.762-2.707
5Y-10.473-6.363-4.110
10Y-78.635-7.055-71.580
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Egetis Therapeutics AB (publ):

  • The EOD is -6.401. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -5.421. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -8.008. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-6.401MRQ-5.421-0.980
MRQ-5.421TTM-8.008+2.586
TTM-8.008YOY-8.301+0.293
TTM-8.0085Y-11.057+3.050
5Y-11.05710Y-79.313+68.256
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-6.401-3.299-3.102
MRQ-5.421-2.742-2.679
TTM-8.008-3.801-4.207
YOY-8.301-4.402-3.899
3Y-8.318-5.140-3.178
5Y-11.057-8.483-2.574
10Y-79.313-9.296-70.017
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price ofΒ Egetis is to cheap or to expensiveΒ compared to its book value.

  • At or below 1 is considered healthyΒ (always compare to Biotechnology industry mean).
  • A PB ratio of 3.33 means the investor is paying kr3.33Β for each kr1 in book value.

Let's take a look of the Price to Book Ratio trends of Egetis Therapeutics AB (publ):

  • The EOD is 3.930. Based on the equity, the company is fair priced.
  • The MRQ is 3.328. Based on the equity, the company is fair priced.
  • The TTM is 4.613. Based on the equity, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD3.930MRQ3.328+0.601
MRQ3.328TTM4.613-1.284
TTM4.613YOY3.755+0.858
TTM4.6135Y4.520+0.093
5Y4.52010Y64.650-60.130
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD3.9302.113+1.817
MRQ3.3281.856+1.472
TTM4.6132.125+2.488
YOY3.7552.454+1.301
3Y3.9132.492+1.421
5Y4.5203.668+0.852
10Y64.6504.364+60.286
4.6.2. Total Gains per Share
3rd party ad coffee SUPPORTERis ad-free.

6. Financial Statements




6.1. Latest Balance Sheet

Balance Sheet of 2025-03-31. Currency in SEK. All numbers in thousands.

Summary
Total Assets724,100
Total Liabilities290,800
Total Stockholder Equity433,300
 As reported
Total Liabilities 290,800
Total Stockholder Equity+ 433,300
Total Assets = 724,100

Assets

Total Assets724,100
Total Current Assets306,100
Long-term Assets418,000
Total Current Assets
Cash And Cash Equivalents 272,800
Net Receivables 32,600
Inventory 700
Total Current Assets  (as reported)306,100
Total Current Assets  (calculated)306,100
+/-0
Long-term Assets
Property Plant Equipment 10,600
Intangible Assets 404,400
Long-term Assets Other 900
Long-term Assets  (as reported)418,000
Long-term Assets  (calculated)415,900
+/- 2,100

Liabilities & Shareholders' Equity

Total Current Liabilities199,700
Long-term Liabilities91,100
Total Stockholder Equity433,300
Total Current Liabilities
Short-term Debt 29,200
Short Long Term Debt 29,200
Accounts payable 19,700
Other Current Liabilities 150,800
Total Current Liabilities  (as reported)199,700
Total Current Liabilities  (calculated)228,900
+/- 29,200
Long-term Liabilities
Long term Debt 69,500
Long-term Liabilities Other 7,800
Long-term Liabilities  (as reported)91,100
Long-term Liabilities  (calculated)77,300
+/- 13,800
Total Stockholder Equity
Common Stock20,400
Retained Earnings -1,673,200
Other Stockholders Equity 2,086,100
Total Stockholder Equity (as reported)433,300
Total Stockholder Equity (calculated)433,300
+/-0
Other
Capital Stock20,400
Cash and Short Term Investments 272,800
Common Stock Shares Outstanding 361,882
Liabilities and Stockholders Equity 724,100
Net Debt -174,100
Net Invested Capital 532,000
Net Working Capital 106,400
Property Plant and Equipment Gross 10,600
Short Long Term Debt Total 98,700



6.2. Balance Sheets Structured

Currency in SEK. All numbers in thousands.

 Trend2025-03-312024-12-312024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-31
> Total Assets 
0
0
0
8,492
12,072
118,243
115,023
91,425
82,357
71,630
67,501
60,457
50,445
61,325
56,927
51,011
42,611
51,052
44,229
103,468
88,452
73,889
62,523
52,361
44,668
41,224
26,040
396,435
386,618
368,003
357,230
315,368
300,048
281,121
254,241
242,037
266,050
324,370
291,276
270,073
234,105
193,204
164,000
893,967
850,758
831,510
777,377
569,268
534,822
661,118
617,600
561,100
676,100
608,800
534,100
760,200
700,000
646,600
577,500
792,300
724,100
724,100792,300577,500646,600700,000760,200534,100608,800676,100561,100617,600661,118534,822569,268777,377831,510850,758893,967164,000193,204234,105270,073291,276324,370266,050242,037254,241281,121300,048315,368357,230368,003386,618396,43526,04041,22444,66852,36162,52373,88988,452103,46844,22951,05242,61151,01156,92761,32550,44560,45767,50171,63082,35791,425115,023118,24312,0728,492000
   > Total Current Assets 
0
0
0
797
2,583
106,376
97,917
91,413
82,296
71,571
67,442
60,399
50,389
61,269
56,873
50,956
42,557
50,998
44,176
103,416
88,400
73,837
62,472
52,361
44,668
41,224
26,040
396,435
386,618
368,003
357,230
315,368
300,048
281,121
254,241
242,037
265,767
324,140
291,100
269,950
233,912
193,069
163,918
299,871
257,031
237,678
183,428
152,902
119,129
246,098
203,200
147,400
259,100
192,700
118,500
345,900
285,800
232,500
164,400
380,100
306,100
306,100380,100164,400232,500285,800345,900118,500192,700259,100147,400203,200246,098119,129152,902183,428237,678257,031299,871163,918193,069233,912269,950291,100324,140265,767242,037254,241281,121300,048315,368357,230368,003386,618396,43526,04041,22444,66852,36162,47273,83788,400103,41644,17650,99842,55750,95656,87361,26950,38960,39967,44271,57182,29691,41397,917106,3762,583797000
       Cash And Cash Equivalents 
0
0
0
568
2,334
106,165
97,659
90,548
81,646
68,608
65,487
58,808
48,264
59,116
54,910
49,302
41,388
47,799
40,675
100,043
86,070
69,586
59,313
50,360
43,684
31,666
23,590
393,998
382,041
363,748
354,342
309,531
294,342
267,053
250,267
229,876
258,036
319,549
286,748
255,101
221,141
184,470
159,424
287,850
249,775
207,411
173,150
143,965
106,785
233,216
190,100
127,700
243,500
179,200
85,000
303,300
251,700
192,600
129,900
351,000
272,800
272,800351,000129,900192,600251,700303,30085,000179,200243,500127,700190,100233,216106,785143,965173,150207,411249,775287,850159,424184,470221,141255,101286,748319,549258,036229,876250,267267,053294,342309,531354,342363,748382,041393,99823,59031,66643,68450,36059,31369,58686,070100,04340,67547,79941,38849,30254,91059,11648,26458,80865,48768,60881,64690,54897,659106,1652,334568000
       Net Receivables 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
4,001
730
9,696
374
10,068
6,027
2,000
1,853
6,904
3,564
7,052
471
6,843
3,811
27,531
6,687
6,795
6,141
7,551
4,600
10,200
9,600
10,800
27,600
36,400
28,200
20,900
22,300
23,600
32,600
32,60023,60022,30020,90028,20036,40027,60010,8009,60010,2004,6007,5516,1416,7956,68727,5313,8116,8434717,0523,5646,9041,8532,0006,02710,0683749,6967304,0010000000000000000000000000000000
       Other Current Assets 
0
0
0
229
249
211
258
865
650
2,963
1,955
1,591
2,125
2,153
1,963
1,654
1,169
3,199
3,501
3,162
2,330
4,251
3,159
2,001
984
9,558
2,450
2,695
4,577
4,255
2,888
3,271
4,976
4,372
3,600
3,230
2,290
2,591
2,499
9,649
11,770
2,469
4,023
5,000
2,494
2,741
4,411
1,448
7,898
8,403
7,700
15,300
11,100
9,200
11,500
13,700
8,800
18,000
33,900
28,100
0
028,10033,90018,0008,80013,70011,5009,20011,10015,3007,7008,4037,8981,4484,4112,7412,4945,0004,0232,46911,7709,6492,4992,5912,2903,2303,6004,3724,9763,2712,8884,2554,5772,6952,4509,5589842,0013,1594,2512,3303,1623,5013,1991,1691,6541,9632,1532,1251,5911,9552,963650865258211249229000
   > Long-term Assets 
0
0
0
7,695
9,489
11,867
17,105
12
61
59
59
57
57
56
56
55
54
54
53
52
52
52
51
0
0
0
0
0
0
0
0
0
0
0
0
0
283
230
176
123
193
134
81
594,097
593,727
593,832
593,949
416,366
415,693
415,020
414,400
413,700
417,000
416,000
415,600
414,300
414,200
414,100
413,100
412,200
418,000
418,000412,200413,100414,100414,200414,300415,600416,000417,000413,700414,400415,020415,693416,366593,949593,832593,727594,0978113419312317623028300000000000005152525253545455565657575959611217,10511,8679,4897,695000
       Property Plant Equipment 
0
0
0
4
15
14
13
12
11
10
9
8
7
6
6
5
4
4
3
3
2
2
1
1
0
0
0
0
0
0
0
0
0
0
0
0
283
230
176
123
193
134
81
4,741
4,642
5,019
4,620
4,274
3,872
3,470
3,000
2,700
6,100
5,500
5,000
4,400
3,700
3,800
3,200
2,600
10,600
10,6002,6003,2003,8003,7004,4005,0005,5006,1002,7003,0003,4703,8724,2744,6205,0194,6424,74181134193123176230283000000000000112233445667891011121314154000
       Intangible Assets 
0
0
0
7,691
9,474
11,853
17,092
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
589,356
589,085
588,815
588,544
411,307
411,036
410,766
410,500
410,300
409,900
409,700
409,400
409,200
408,900
408,600
408,300
408,000
404,400
404,400408,000408,300408,600408,900409,200409,400409,700409,900410,300410,500410,766411,036411,307588,544588,815589,085589,35600000000000000000000000000000000000017,09211,8539,4747,691000
       Other Assets 
0
0
0
0
0
0
0
0
0
0
0
1
-1
0
-2
0
109
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-1
1
1
-1
581,784
581,782
581,784
404,817
404,817
-1
404,900
404,800
0
100
404,700
0
0
0
0
0
0
000000404,7001000404,800404,900-1404,817404,817581,784581,782581,784-111-1000000000000000000000001090-20-1100000000000
> Total Liabilities 
0
0
0
1,502
908
5,194
2,065
3,893
4,102
3,924
5,437
6,516
4,535
2,903
3,014
4,057
2,434
3,367
7,810
12,810
9,945
5,615
5,680
4,329
3,481
12,021
4,769
6,873
9,337
5,586
21,957
11,657
12,148
21,432
12,742
22,675
23,598
24,595
23,394
25,197
32,047
27,209
22,567
264,340
240,249
255,104
222,967
42,230
35,761
26,146
35,000
54,900
47,400
57,900
67,200
214,600
227,500
245,200
258,900
299,400
290,800
290,800299,400258,900245,200227,500214,60067,20057,90047,40054,90035,00026,14635,76142,230222,967255,104240,249264,34022,56727,20932,04725,19723,39424,59523,59822,67512,74221,43212,14811,65721,9575,5869,3376,8734,76912,0213,4814,3295,6805,6159,94512,8107,8103,3672,4344,0573,0142,9034,5356,5165,4373,9244,1023,8932,0655,1949081,502000
   > Total Current Liabilities 
0
0
0
1,502
908
5,194
2,065
3,893
4,102
3,924
5,436
6,516
4,536
2,903
3,015
4,057
2,434
3,368
7,810
12,810
9,945
5,615
5,680
4,329
3,481
12,020
4,769
6,874
9,337
5,586
21,958
11,657
12,148
21,432
12,742
22,675
23,482
24,478
23,277
25,081
32,018
27,174
22,481
70,141
49,419
67,153
34,800
39,170
32,959
23,583
32,600
49,400
38,100
52,100
61,100
103,900
112,800
149,300
167,000
204,200
199,700
199,700204,200167,000149,300112,800103,90061,10052,10038,10049,40032,60023,58332,95939,17034,80067,15349,41970,14122,48127,17432,01825,08123,27724,47823,48222,67512,74221,43212,14811,65721,9585,5869,3376,8744,76912,0203,4814,3295,6805,6159,94512,8107,8103,3682,4344,0573,0152,9034,5366,5165,4363,9244,1023,8932,0655,1949081,502000
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
0
0
0
-38,847
-69,154
-41,039
1,614
1,500
1,517
1,532
0
1,600
0
0
0
7,400
12,500
19,500
26,800
30,100
29,200
29,20030,10026,80019,50012,5007,4000001,60001,5321,5171,5001,614-41,039-69,154-38,8470001000000000000000000000000000000000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
5,200
12,500
19,500
26,800
30,100
29,200
29,20030,10026,80019,50012,5005,2000000000000000000000000000000000000000000000000000000000
       Accounts payable 
0
0
0
1,021
377
730
737
1,432
1,730
2,003
2,766
2,331
984
809
434
1,278
189
1,521
4,782
9,967
5,102
2,507
2,481
1,766
1,102
9,449
2,271
4,678
6,022
3,538
19,023
5,972
6,018
15,652
6,814
15,174
16,835
14,476
2,909
11,207
13,264
10,089
3,904
15,611
3,716
34,751
8,795
4,600
5,692
4,912
7,000
20,000
7,200
21,200
11,300
28,700
14,700
33,800
19,600
25,700
19,700
19,70025,70019,60033,80014,70028,70011,30021,2007,20020,0007,0004,9125,6924,6008,79534,7513,71615,6113,90410,08913,26411,2072,90914,47616,83515,1746,81415,6526,0185,97219,0233,5386,0224,6782,2719,4491,1021,7662,4812,5075,1029,9674,7821,5211891,2784348099842,3312,7662,0031,7301,4327377303771,021000
       Other Current Liabilities 
0
0
0
439
460
4,370
1,195
2,329
2,218
1,742
2,437
4,185
3,409
1,941
2,418
2,779
2,218
1,814
2,711
2,843
4,843
3,108
3,199
2,563
2,379
2,571
2,498
2,195
3,315
2,048
2,935
5,685
6,130
5,780
5,928
7,501
6,647
10,002
20,368
13,873
18,754
17,085
18,577
13,401
5,000
5,923
26,005
33,070
25,750
17,139
25,600
27,800
30,900
30,900
49,800
67,600
85,600
96,000
120,600
148,200
150,800
150,800148,200120,60096,00085,60067,60049,80030,90030,90027,80025,60017,13925,75033,07026,0055,9235,00013,40118,57717,08518,75413,87320,36810,0026,6477,5015,9285,7806,1305,6852,9352,0483,3152,1952,4982,5712,3792,5633,1993,1084,8432,8432,7111,8142,2182,7792,4181,9413,4094,1852,4371,7422,2182,3291,1954,370460439000
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
0
1
0
-1
0
-1
0
0
-1
0
0
0
0
0
0
0
1
0
-1
0
0
-1
0
0
0
0
0
116
117
117
116
29
35
86
194,199
190,830
187,951
188,167
3,060
2,802
2,563
2,400
5,500
9,300
5,800
6,100
110,700
114,700
95,900
91,900
95,200
91,100
91,10095,20091,90095,900114,700110,7006,1005,8009,3005,5002,4002,5632,8023,060188,167187,951190,830194,19986352911611711711600000-100-1010000000-100-10-1010000000000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
35
86
190,673
187,609
184,542
185,262
410
537
686
900
4,400
0
2,500
3,400
0
0
0
0
0
0
0000003,4002,50004,400900686537410185,262184,542187,609190,673863500000000000000000000000000000000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
581,784
581,784
581,784
581,784
404,817
404,817
404,817
404,800
404,800
0
404,800
404,800
0
0
0
0
0
0
000000404,800404,8000404,800404,800404,817404,817404,817581,784581,784581,784581,7840000000000000000000000000000000000000000000
> Total Stockholder Equity
0
0
0
6,990
11,165
113,050
112,957
87,532
78,255
67,706
62,064
53,941
45,910
58,422
53,913
46,953
40,177
47,684
36,419
90,658
78,507
68,274
56,843
48,032
41,186
29,203
21,271
389,562
377,281
362,416
335,272
303,711
287,900
259,688
241,498
219,361
242,452
299,775
267,883
244,876
202,058
165,995
141,433
629,627
610,509
576,407
554,411
527,038
499,061
634,972
582,600
506,200
628,700
550,900
467,000
545,600
472,600
401,500
318,600
492,800
433,300
433,300492,800318,600401,500472,600545,600467,000550,900628,700506,200582,600634,972499,061527,038554,411576,407610,509629,627141,433165,995202,058244,876267,883299,775242,452219,361241,498259,688287,900303,711335,272362,416377,281389,56221,27129,20341,18648,03256,84368,27478,50790,65836,41947,68440,17746,95353,91358,42245,91053,94162,06467,70678,25587,532112,957113,05011,1656,990000
   Common Stock
0
0
0
301
696
696
1,066
1,066
1,066
1,066
1,066
1,066
1,066
1,154
1,154
1,154
1,154
1,243
1,243
1,492
1,492
1,494
1,494
1,494
1,494
1,494
1,494
2,561
2,561
2,561
2,561
2,561
2,561
2,561
2,561
2,561
2,561
2,818
2,818
2,818
2,818
2,818
2,818
8,688
8,688
8,688
8,688
8,688
8,688
11,294
11,300
11,300
13,100
13,100
13,100
15,400
15,400
15,400
15,400
20,400
20,400
20,40020,40015,40015,40015,40015,40013,10013,10013,10011,30011,30011,2948,6888,6888,6888,6888,6888,6882,8182,8182,8182,8182,8182,8182,5612,5612,5612,5612,5612,5612,5612,5612,5612,5611,4941,4941,4941,4941,4941,4941,4921,4921,2431,2431,1541,1541,1541,1541,0661,0661,0661,0661,0661,0661,066696696301000
   Retained Earnings Total Equity0000000000000000000000000000000000000000000000000000000000000
   Accumulated Other Comprehensive Income 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
1
1
1
0
0
0
0
0
0
1
0
0
0
0
1
1
0
0
1
1
1
0
0
-1
0
-1
0
0
448
645
868
1,402
1,305
2,145
3,114
4,600
6,100
7,500
9,100
11,400
16,700
18,600
19,400
0
0
0
00019,40018,60016,70011,4009,1007,5006,1004,6003,1142,1451,3051,40286864544800-10-100111001100001000000111100000000000000
   Capital Surplus 0000000000000000000000000000000000000000000000000000000000000
   Treasury Stock0000000000000000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
10,489
13,316
117,689
119,712
119,712
86,466
86,465
86,465
86,732
52,876
71,347
71,347
71,348
45,798
65,890
65,890
137,586
89,166
90,374
90,374
90,374
46,538
46,538
46,538
615,861
387,001
388,325
388,518
617,944
617,944
617,944
618,598
618,597
618,600
705,027
705,277
705,278
705,278
705,387
705,551
1,261,741
1,262,837
1,262,837
1,262,837
1,262,838
1,262,837
1,428,416
1,428,400
1,428,400
1,622,600
1,622,600
1,634,000
1,780,000
1,780,000
1,780,000
1,802,700
2,082,500
2,086,100
2,086,1002,082,5001,802,7001,780,0001,780,0001,780,0001,634,0001,622,6001,622,6001,428,4001,428,4001,428,4161,262,8371,262,8381,262,8371,262,8371,262,8371,261,741705,551705,387705,278705,278705,277705,027618,600618,597618,598617,944617,944617,944388,518388,325387,001615,86146,53846,53846,53890,37490,37490,37489,166137,58665,89065,89045,79871,34871,34771,34752,87686,73286,46586,46586,466119,712119,712117,68913,31610,489000



6.3. Balance Sheets

Currency in SEK. All numbers in thousands.




6.4. Cash Flows

Currency in SEK. All numbers in thousands.




6.5. Income Statements

Currency in SEK. All numbers in thousands.


6.6. Latest Income Statement

Income Statement (annual), 2024-12-31. Currency in SEK. All numbers in thousands.

Gross Profit (+$)
totalRevenue46,100
Cost of Revenue-11,600
Gross Profit34,50034,500
 
Operating Income (+$)
Gross Profit34,500
Operating Expense-363,900
Operating Income-329,400-329,400
 
Operating Expense (+$)
Research Development146,200
Selling General Administrative105,600
Selling And Marketing Expenses109,700
Operating Expense363,900361,500
 
Net Interest Income (+$)
Interest Income16,500
Interest Expense-25,900
Other Finance Cost-0
Net Interest Income-9,400
 
Pretax Income (+$)
Operating Income-329,400
Net Interest Income-9,400
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-343,200-315,600
EBIT - interestExpense = -343,200
-343,300
-317,700
Interest Expense25,900
Earnings Before Interest and Taxes (EBIT)-317,300-317,300
Earnings Before Interest and Taxes (EBITDA)-317,400
 
After tax Income (+$)
Income Before Tax-343,200
Tax Provision-300
Net Income From Continuing Ops-343,500-343,500
Net Income-343,600
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses375,500
Total Other Income/Expenses Net-13,8009,400
 

Technical Analysis of Egetis
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Egetis. The general trend of Egetis is NEUTRAL with 0.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Egetis's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (0.0%) Bearish trend (0.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Egetis Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

SupportΒ is a price level at which demand for an asset is strong enough to prevent the price from falling further.
ResistanceΒ is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Egetis Therapeutics AB (publ).

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 5 < 5.04 < 5.17.

The bearish price targets are: 3.825 > 3.025.

Know someone who trades $EGTX? Share this with them.πŸ‘‡

Egetis Therapeutics AB (publ) Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows theΒ moving averageΒ of the selected period.

  • Moving averages are laggingΒ trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Egetis Therapeutics AB (publ). The current mas is .

The long score for the Moving Averages is 7/14.
The longshort score for the Moving Averages is 0/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 > MA 100: The MA 20 is higher than the MA 100. +1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close > MA 100: The price is above the MA 100. +1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Egetis Therapeutics AB (publ) Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows theΒ momentumΒ of theΒ selected period based on two moving averages.

  • MACD is aΒ lagging momentumΒ indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Egetis Therapeutics AB (publ). The current macd is 0.19691397.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Egetis price going down in the near term. -2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Egetis. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Egetis price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Egetis Therapeutics AB (publ) Daily Moving Average Convergence/Divergence (MACD) ChartEgetis Therapeutics AB (publ) Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Egetis Therapeutics AB (publ). The current adx is 34.57.

The long score for the Directional Movement Index (DMI) is 3/7.
The longshort score for the Directional Movement Index (DMI) is 3/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Egetis shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX > 25 && ADX trending down: The ADX is above 25 and indicates a strong bullish trend. The ADX is declining, the bullish trend is weakening. Could be a potential reversal to the downside. +2
Egetis Therapeutics AB (publ) Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • ShowsΒ the current trend.
  • ShowsΒ potential entry signals.
  • ShowsΒ Β potential exit signals.
  • Can be used to placeΒ trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Egetis Therapeutics AB (publ). The current sar is 4.41128984.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Egetis Therapeutics AB (publ) Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentumΒ indicator, meaning the signals are instant.
  • RangesΒ between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Egetis Therapeutics AB (publ). The current rsi is 58.01. The current phase is Correction in bear market.

The long score for the Relative Strength Index (RSI) is 4/13.
The longshort score for the Relative Strength Index (RSI) is 4/(-13 +13).

  • Correction in bear market: Extended price decline in a downtrend, significant pullback. Consider reducing exposure, wait for signs of trend reversal.
  • Trending up: The RSI is trending up. +1
Egetis Therapeutics AB (publ) Daily Relative Strength Index (RSI) ChartEgetis Therapeutics AB (publ) Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

ComparesΒ a certain price to multiple prices ranging over time.

  • LeadingΒ momentumΒ indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • RangesΒ between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Egetis Therapeutics AB (publ). The current phase is Correction in bear market.

The long score for the Stochastic Oscillator is 1/6.
The longshort score for the Stochastic Oscillator is -2/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Egetis price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Egetis Therapeutics AB (publ) Daily Stochastic Oscillator ChartEgetis Therapeutics AB (publ) Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero,Β the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Egetis Therapeutics AB (publ). The current cci is 39.90.

Egetis Therapeutics AB (publ) Daily Commodity Channel Index (CCI) ChartEgetis Therapeutics AB (publ) Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Egetis Therapeutics AB (publ). The current cmo is 13.67.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Egetis Therapeutics AB (publ) Daily Chande Momentum Oscillator (CMO) ChartEgetis Therapeutics AB (publ) Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

Β Shows the current price relative to the highest high over the last 14 days.
Β 

  • Lagging momentum indicator
  • Ranging between 0 andΒ -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Egetis Therapeutics AB (publ). The current willr is -36.64596273.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Egetis is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Egetis Therapeutics AB (publ) Daily Williams %R ChartEgetis Therapeutics AB (publ) Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversoldΒ 

Score

Let's take a look at the Bollinger Bands of Egetis Therapeutics AB (publ).

Egetis Therapeutics AB (publ) Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Egetis Therapeutics AB (publ). The current atr is 0.25429319.

Egetis Therapeutics AB (publ) Daily Average True Range (ATR) ChartEgetis Therapeutics AB (publ) Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

Β Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Egetis Therapeutics AB (publ). The current obv is -6,019,370.

Egetis Therapeutics AB (publ) Daily On-Balance Volume (OBV) ChartEgetis Therapeutics AB (publ) Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Egetis Therapeutics AB (publ). The current mfi is 74.46.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Egetis Therapeutics AB (publ) Daily Money Flow Index (MFI) ChartEgetis Therapeutics AB (publ) Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Egetis Therapeutics AB (publ).

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2025-02-18DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-02-19STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-20STOCH LONG EXITThe %K line crosses below the %D line.
2025-02-21STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-02-25RSI LONG ENTRY SHORT CLOSE30 crossover to upside
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-02-28STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-04CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-03-05MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-03-06STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-12MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-03-14STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-18MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2025-03-19CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-03-21STOCH SHORT EXITThe %K line crosses above the %D line.
2025-03-25MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2025-03-26STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-03-28SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2025-03-31RSI LONG ENTRY SHORT CLOSE30 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-04-02WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-04-03DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2025-04-04STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-04-07SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-04-08STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-09DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-04-10STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-11STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-04-15CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-04-17MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2025-04-22STOCH SHORT EXITThe %K line crosses above the %D line.
2025-04-23MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-04-24DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2025-04-25SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2025-04-29STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-05-02DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-05DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-08DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2025-05-09DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-12CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-05-13STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-05-14DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-05-15MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-05-16BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-05-20STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-22STOCH LONG EXITThe %K line crosses below the %D line.
2025-05-26RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-05-28STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-05-30MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-06-04CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-06-05STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-09BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-06-10STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-06-11RSI SHORT ENTRY LONG CLOSE70 crossover to downside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-06-12ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-06-13RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2025-06-17MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2025-06-18SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2025-06-23CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-06-24MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-06-26STOCH LONG EXITThe %K line crosses below the %D line.
2025-06-27MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-06-30SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2025-07-02CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-07-04STOCH LONG EXITThe %K line crosses below the %D line.
2025-07-08STOCH SHORT EXITThe %K line crosses above the %D line.
2025-07-09MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2025-07-10STOCH SHORT EXITThe %K line crosses above the %D line.
2025-07-11STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2025-07-14MFI SHORT ENTRY LONG CLOSE80 crossover to downside

6.3. Candlestick Patterns

Egetis Therapeutics AB (publ) Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Egetis Therapeutics AB (publ) based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5058.009
Ma 20Greater thanMa 504.526
Ma 50Greater thanMa 1004.007
Ma 100Greater thanMa 2004.081
OpenGreater thanClose4.550
Total2/5 (40.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Egetis with someone you think should read this too:
  • Are you bullish or bearish on Egetis? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Egetis? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Egetis Therapeutics AB (publ)

I send you an email if I find something interesting about Egetis Therapeutics AB (publ).


Comments

How you think about this?

Leave a comment

Stay informed about Egetis Therapeutics AB (publ).

Receive notifications about Egetis Therapeutics AB (publ) in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.